Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Recruiting 5Completed 4Active not recruiting 3Unknown 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 3Thoracic 2Genitourinary 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 24Pancreatic Neoplasms 14Stomach Neoplasms 12Rectal Neoplasms 12Squamous Cell Carcinoma of Head and Neck 9Esophageal Neoplasms 9Colonic Neoplasms 9Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Cholangiocarcinoma 4Breast Neoplasms 4Anus Neoplasms 4Ovarian Neoplasms 3Nasopharyngeal Carcinoma 2Melanoma 2Hepatoblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Unresectable Colorectal Cancer 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × Fluorouracil × Clear all
NCT05891171 2026-06-05

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡